Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScRNA-seq of MC38 syngeneic colorectal tumors after FAP-CAR mRNA-LNP therapy

ABSTRACT: This study investigates the therapeutic potential of an mRNA–lipid nanoparticle (LNP)-based strategy delivering fibroblast activation protein (FAP)-specific chimeric antigen receptor (CAR) mRNA in colorectal cancer. Syngeneic colorectal mouse tumor models were treated with FAP-CAR mRNA-LNPs, and single-cell RNA sequencing (scRNA-seq) of tumor tissues was performed. The analysis aimed to explore mechanisms of tumor relapse following treatment, with a particular focus on the MIF–CD74 signaling axis. The data revealed heterogeneous immune and stromal cell states, highlighting immunosuppressive pathways associated with relapse.

ORGANISM(S): Mus musculus

PROVIDER: GSE307699 | GEO | 2025/12/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-seq of colorectal cancer patient-derived xenograft (PDX) tumors treated with FAP-CAR mRNA-LNP therapy

Project description:This study investigates the therapeutic potential of an mRNA–lipid nanoparticle (LNP)-based strategy to deliver fibroblast activation protein (FAP)-specific chimeric antigen receptor (CAR) mRNA in colorectal cancer. Patient-derived xenograft (PDX) tumor models (PDX-1 and PDX-2) were treated by splenocytes with FAP-CAR mRNA-LNPs, including wild-type or 7SL1 knock-in splenocytes, in comparison with PBS controls. RNA sequencing of the tumor tissues was performed to profile transcriptional responses associated with treatment efficacy or resistance. Differential expression and pathway enrichment analyses revealed distinct immune and stromal gene programs, including HOX family transcription factor activation in resistant tumors.

2025-12-10 | GSE307698 | GEO

ATAC-seq of colorectal cancer patient-derived xenograft (PDX) tumors treated with FAP-CAR mRNA-LNP therapy

Project description:This study investigates the therapeutic potential of an mRNA–lipid nanoparticle (LNP)-based strategy to deliver fibroblast activation protein (FAP)-specific chimeric antigen receptor (CAR) mRNA in colorectal cancer. Patient-derived xenograft (PDX) tumor models (PDX-1 and PDX-2) were treated by splenocytes (7SL1 knock-in) with FAP-CAR mRNA-LNPs, in comparison with PBS controls. ATAC sequencing of the tumor tissues was performed to profile transcriptional responses associated with treatment efficacy or resistance. Analysis revealed distinct chromatin accessibility programs, including activation of HOX gene clusters in resistant tumors, highlighting potential epigenetic mechanisms of therapeutic escape.

2025-12-10 | GSE307697 | GEO

scRNA-seq of MC38 syngeneic colorectal tumors after FAP-CAR mRNA-LNP therapy

Project description:scRNA-seq of MC38 syngeneic colorectal tumors after FAP-CAR mRNA-LNP therapy

| PRJNA1322559 | ENA

In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis

Project description:In this study, we aimed to determine the efficacy of in vivo chimeric antigen receptor (CAR) T cell therapy, generated by targeted lipid nanoparticles (t-LNPs), as an anti-fibrotic in metabolic dysfunction-associated steatotic liver disease. Hepatic fibrosis is a key predictor of mortality in liver disease, driven by fibrogenic hepatic stellate cells (HSCs). In heart, chimeric antigen receptor (CAR) T cells targeting fibroblast activation protein alpha (FAP) reduce murine cardiac fibrosis. However, the value of this approach in liver is unknown. We explored the anti-fibrotic potential of in vivo-generated anti-FAP CAR T cells in metabolic dysfunction-associated steatohepatitis (MASH), a highly prevalent disease with no approved anti-fibrotic therapies. We first established that FAP expression in both human and murine MASH is specific to HSCs. We then used flow cytometry, Sirius Red morphometry, digital pathology analysis, and single nuclear RNA-sequencing to assess the impact of anti-FAP CAR T cell therapy on murine MASH. Anti-CD5 targeted-LNPs carrying anti-FAPCAR mRNA generate activated, transient anti-FAP CAR T cells, which significantly reduced fibrosis by depleting pro-fibrogenic HSCs, and by modulating immune cells, endothelial cells and hepatocytes in a non-cell autonomous manner to mitigate inflammation and restore hepatic homeostasis. These findings reinforce the potential of in vivo CAR T therapy to attenuate a highly morbid and pervasive liver disease through its integrated, multicellular salutary effects.

2025-11-05 | GSE309046 | GEO

MiNK-215: Allogeneic FAP-CAR-IL15 iNKT therapy remodels tumor stroma to enhance anti-tumor immunity

Project description:Cellular immunotherapies show remarkable efficacy against hematological malignancies; but face challenges against solid tumors largely attributed to the lack of tumor-specific antigens and immunosuppressive tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs), expressing fibroblast activation protein (FAP) are key contributors in shaping this immunosuppressive landscape, yet effective targeting strategies remain an ongoing challenge. Here, we describe MiNK-215, a novel allogeneic human invariant natural killer T (iNKT) cell therapy, engineered to express a FAP-targeting chimeric antigen receptor (CAR) and secrete interleukin-15 (IL-15) to remodel the TME and enhance anti-tumor activity. MiNK-215 modulated multifunctional immune responses by enhancing T cell responsiveness, dendritic cell activation, M1 macrophage polarization, and tumor killing. In a lung tumor mouse model, MiNK-215 depleted FAP+ CAFs, enhanced antigen-specific T cell infiltration, and promoted durable anti-tumor immunity without off-target toxicity. These findings extended to human organoid models of treatment-refractory Microsatellite Stable Colorectal Cancer (MSS-CRC) liver metastases, establishing FAP-CAR iNKT cells as a promising strategy to overcome immunotherapy resistance in solid tumors.

2025-04-16 | GSE294754 | GEO

ATAC-seq of colorectal cancer patient-derived xenograft (PDX) tumors treated with FAP-CAR mRNA-LNP therapy

Project description:ATAC-seq of colorectal cancer patient-derived xenograft (PDX) tumors treated with FAP-CAR mRNA-LNP therapy

| PRJNA1322555 | ENA

RNA-seq of colorectal cancer patient-derived xenograft (PDX) tumors treated with FAP-CAR mRNA-LNP therapy

Project description:RNA-seq of colorectal cancer patient-derived xenograft (PDX) tumors treated with FAP-CAR mRNA-LNP therapy

| PRJNA1322556 | ENA

Transcriptomic profiling of FAP+ fibroblasts

Project description:FAP+ cells had been reported to be present only in healing wounds and at sites of tissue remodelling. We have found FAP+ cells in many normal tissues and aimed to investigate whether these cells were related or whether FAP is upregulated in response to an external stimulus on a variety of cells. Furthermore we wanted to investigate whether FAP+ cells are simply fibroblasts and so compared their transcriptomic profiles to that of a typical fibroblastic population, the murine embryonic fibroblast. FAP+ cells were sorted from two mesenchymal tissues, visceral adipose and skeletal muscle, and from an epithelial organ, the pancreas. These were compared to MEFs. Cells were isolated in duplicate experiments and these were analysed separately. These were compared to previously published publically available CD4+ T-cell subset data.

2013-07-15 | E-GEOD-39438 | biostudies-arrayexpress

The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory

Project description:Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against coronavirus disease in 2019 (COVID-19). Clinical trials and ongoing vaccinations present with very high protection levels with varying degrees of side effects. However, the nature of the reported side effects remains poorly defined. Here we present evidence that LNPs used in many preclinical studies are highly inflammatory in mice. Intradermal injection of these LNPs led to rapid and robust inflammatory responses, characterized by massive neutrophil infiltration, activation of diverse inflammatory pathways, and production of various inflammatory cytokines and chemokines. The same dose of LNP delivered intranasally led to similar inflammatory responses in the lung and resulted in a high mortality rate. In summary, here we show that the LNPs used for many preclinical studies are highly inflammatory. Thus, their potent adjuvant activity and reported superiority comparing to other adjuvants in supporting the induction of adaptive immune responses could stem from their inflammatory nature. Furthermore, the preclinical LNPs are similar to the ones used for human vaccines, which could also explain the observed side effects in humans using this platform.

2021-03-16 | GSE167521 | GEO

Transcription profiling of human melanoma LOX cells to investigate the effect of Seprase/FAP alpha on metastatis

Project description:In order to detect the molecular mechanism of seprase involved in tumor metastasis, a comparison of gene expression pattern was made between two groups of human melanoma LOX cell sublines, one is transfected with mock vector expressing GFP only (GUS-1<GSM30738>, GUS-2<GSM30729> and GUS-3<GSM30730>) and the other with pGUS expressing GFP and siRNA targeting mRNA of seprase/FAP alpha (sep-1<GSM30731>, sep-2<GSM30732> and sep-3<GSM30740>).

2008-10-25 | E-GEOD-1773 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data